Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
Corvus Pharmaceuticals’ major shareholder OrbiMed filed an ownership update after Corvus completed an underwritten public offering of 7,900,677 common shares at $22.15 per share. Following this offering, OrbiMed Private Investments V, LP beneficially owns 8,609,091 shares, or about 10.3% of Corvus’s common stock, including pre-funded warrants for 1,444,085 shares.
The filing explains that OrbiMed’s ownership percentage fell by more than 1% due to the increase in Corvus’s shares outstanding, not due to share sales. A 45-day lock-up applies to director Peter Thompson and certain other insiders, limiting most share sales and registration demands after the offering.
Corvus Pharmaceuticals entered an underwriting agreement for an underwritten public stock offering of 7,900,677 shares of common stock at a public offering price of $22.15 per share. Underwriters agreed to buy the shares at $20.821 per share and were granted a 30‑day option to purchase an additional 1,185,101 shares, which they exercised in full on January 22, 2026. After underwriting discounts, commissions and estimated expenses and including the option shares, Corvus expects net proceeds of approximately $188.3 million. The company plans to use these funds for working capital and general corporate purposes, including capital expenditures, research and development for its Phase 3 T cell lymphoma and multiple Phase 2 dermatology and asthma trials, as well as sales, marketing and administrative expenses.
Corvus Pharmaceuticals, Inc. is offering 7,900,677 shares of common stock at $22.15 per share in an underwritten public offering on the Nasdaq Global Market. Underwriters also have a 30‑day option to buy up to 1,185,101 additional shares, implying gross proceeds of about $174.999,995.55 and underwriting discounts and commissions of $10,499,999.73, before expenses.
The company expects net proceeds of approximately $163.6 million, or $188.3 million if the option is fully exercised, and plans to use the cash mainly for working capital and research and development, including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials, plus sales, marketing and administrative expenses. Together with existing cash, cash equivalents and marketable securities, Corvus expects to fund operations into the first quarter of 2028.
Corvus recently reported positive Phase 1 cohort 4 data for soquelitinib in moderate to severe atopic dermatitis, showing a 72% mean reduction in EASI at day 56 versus 40% on placebo and higher EASI 75 and IGA 0/1 response rates, including in patients previously treated with systemic therapies. As of December 31, 2025, it preliminarily estimates cash, cash equivalents and marketable securities of about $56.7 million and has suspended its $100 million at‑the‑market program with Jefferies after selling no shares.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.
Corvus Pharmaceuticals, Inc. reported an insider equity award to its President, CEO and Director, Richard A. Miller. On 12/04/2025 he was granted a stock option to purchase 1,000,000 shares of Corvus common stock at an exercise price of $8.81 per share.
The option expires on 12/04/2035 and the underlying shares vest in equal monthly installments. Specifically, 1/36th of the shares vest each month starting on December 4, 2025, as long as he continues his service relationship with the company. Following this grant, he directly holds 1,000,000 derivative securities in the form of stock options.
Corvus Pharmaceuticals reported that its Chief Business Officer, Jeffrey Arcara, acquired a stock option covering 100,000 shares of common stock on December 4, 2025. The option has an exercise price of $8.81 per share and is held directly.
The underlying shares vest in equal monthly installments, with 1/36 of the shares vesting each month starting from December 4, 2025, as long as Arcara continues his service with the company. The option expires on December 4, 2035, and following this transaction he beneficially owned 100,000 stock options.
Corvus Pharmaceuticals (CRVS) filed its Q3 2025 10‑Q, highlighting a clinical‑stage pipeline and continued operating losses. Cash, cash equivalents and marketable securities were $65.7 million as of September 30, 2025. Q3 operating expenses were $10.6 million, driven by R&D $8.5 million and G&A $2.1 million.
The company reported a Q3 net loss of $10.2 million. For the nine months, net loss was $3.0 million, reflecting a $27.1 million non‑cash gain from the change in fair value of its warrant liability. All common warrants from the May 2024 financing were exercised, delivering $54.3 million in proceeds and reducing the warrant liability to zero from $28.9 million at year‑end 2024; current liabilities fell to $8.1 million from $35.4 million.
Operating cash outflow was $23.6 million for the nine months, while financing inflows were $36.4 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it may seek additional funding, including under its $100 million at‑the‑market program with no sales to date. Shares outstanding were 74,681,872 as of November 4, 2025.
Corvus Pharmaceuticals (CRVS) filed an 8-K to furnish a press release covering its financial results for the three and nine months ended September 30, 2025, along with a business update. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished and not filed under the Exchange Act. Corvus’s common stock trades on the Nasdaq Global Market under the symbol CRVS.